The global drug eluting balloon (DEB) market is witnessing significant growth as healthcare providers increasingly adopt minimally invasive treatment options for cardiovascular diseases and peripheral artery disorders. Drug eluting balloons are specialized angioplasty balloons coated with therapeutic drugs that are delivered directly to the vessel wall during balloon inflation, helping prevent restenosis while avoiding the need for permanent implants. Their growing clinical acceptance, coupled with advancements in interventional cardiology procedures, is driving widespread adoption across healthcare facilities worldwide. Rising incidences of coronary artery disease, peripheral vascular disease, diabetes-related vascular complications, and an aging population are creating substantial demand for innovative vascular treatment solutions. Furthermore, increasing awareness among physicians regarding the long-term benefits of drug-coated technologies is accelerating market expansion.

Access key findings and insights from our Report in this sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2321

Market Size and Growth

The global drug eluting balloon industry was valued at US$ 571.1 million in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 7.1% from 2023 to 2031. Driven by technological innovations, favorable clinical outcomes, and growing healthcare investments, the market is expected to reach approximately US$ 1.0 billion by the end of 2031. The increasing prevalence of cardiovascular diseases remains one of the primary growth catalysts. In addition, healthcare systems worldwide are emphasizing cost-effective treatment approaches that reduce hospital stays and repeat interventions, making drug eluting balloons an attractive therapeutic option. Continuous product development, expanding regulatory approvals, and growing reimbursement support are expected to further strengthen market growth throughout the forecast period.

Market Segmentation

The drug eluting balloon market can be segmented based on product type, application, end user, and geography. By application, the market is primarily categorized into coronary artery disease and peripheral artery disease treatments. The peripheral artery disease segment continues to gain traction due to rising patient volumes and favorable treatment outcomes. Based on end users, hospitals account for the largest market share owing to the availability of advanced catheterization laboratories and specialized cardiovascular care facilities. Ambulatory surgical centers and specialty clinics are also emerging as important contributors due to the growing shift toward outpatient procedures. From a product perspective, manufacturers are focusing on improving drug coating technologies, balloon deliverability, and procedural efficiency to enhance clinical performance and physician adoption.

Regional Analysis

North America currently represents a significant share of the global drug eluting balloon market due to its advanced healthcare infrastructure, strong reimbursement frameworks, and high prevalence of cardiovascular disorders. Europe remains another key regional market, supported by extensive clinical research activities and early adoption of innovative vascular treatment technologies. Meanwhile, the Asia Pacific region is expected to register the fastest growth during the forecast period. Rapid urbanization, increasing healthcare expenditure, expanding patient populations, and improving access to advanced medical treatments are creating favorable market conditions across countries such as China, India, Japan, and South Korea. Latin America and the Middle East & Africa are also witnessing gradual market development as healthcare modernization initiatives continue to improve treatment accessibility.

Competitive Landscape

The global drug eluting balloon market is moderately consolidated, with leading medical device manufacturers investing heavily in research and development to strengthen their product portfolios and market positions. Key industry participants include Bayer AG, Medtronic, B. Braun Melsungen AG, Cook Medical, Inc., Boston Scientific Corporation, Becton, Dickinson and Company, EuroCor, Terumo Corporation, and Koninklijke Philips N.V. These companies are pursuing strategic initiatives such as product launches, regulatory approvals, partnerships, acquisitions, and geographic expansion to enhance their competitive advantage. Innovation remains a critical differentiator as manufacturers focus on improving drug delivery efficiency, safety profiles, and clinical outcomes.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453